Endothelin Receptor
信号通路图
研究领域
- 抑制剂选择性比较
- 溶解性比较
| 目录号 | 产品目录 | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | 酒精 | ||
| S1456 | Zibotentan (ZD4054) | <1 mg/mL | 24 mg/mL | <1 mg/mL |
| S3051 | Bosentan Hydrate | 0.001 mg/mL | 100 mg/mL | 2 mg/mL |
| S8051 | Macitentan | <1 mg/mL | 100 mg/mL | <1 mg/mL |
| S2097 | Ambrisentan | <1 mg/mL | 76 mg/mL | 22 mg/mL |
| S7883 | BQ-123 | <1 mg/mL | 100 mg/mL | 15 mg/mL |
特异性亚型抑制剂
- Endothelin Receptor抑制剂（5）
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1456 |
Zibotentan (ZD4054)Zibotentan (ZD4054)是一种特异性的Endothelin (ET)A拮抗剂，IC50为21 nM，对ETB没有抑制活性。Phase 3。 |
(E and F) Photomicrograph and quantifications showing reducing in inflammation in steatosis in IL27RA-/-p53H/1 mice treated with ZD4054 (N=9), when compared to sham treated mice (N=7). Chi-square test was used to determine the differences among these two groups. In vivo data with ZD4054 inhibitor was repeated twice with similar results. (i) WT, (ii) IL27RA-/-, (iii) p53H/1, or (iv) IL27RA-/-p53H/1. Dots indicate data from liver of individual mice. Pictures taken at 2003. *P < 0.05. Abbreviation: DAPI, 40,6-diamidino-2-phenylindole.
|
|
| S3051 |
Bosentan HydrateBosentan Hydrate是一种内皮素(ET)受体拮抗剂，靶点有ET-A和ET-B，Ki分别为4.7 nM和95 nM。 |
||
| S8051 |
MacitentanMacitentan是一种口服有效的，非肽类，ETA/ETB(内皮素) receptor双重拮抗剂，IC50为0.5 nM/391 nM。 |
||
| S2097 |
AmbrisentanAmbrisentan是高选择性的内皮素-1A型受体拮抗剂，IC50为18 nM，用于治疗肺动脉高血压（PAH）。 |
||
| S7883 |
BQ-123BQ-123 是一种选择性 endothelin A receptor (ETA) 拮抗剂，IC50 为 7.3 nM。Phase 2。 |
Effects of 0.1% DMSO (as a vehicle), BQ-123 (a selective ETA receptor antagonist), BQ-788 (a selective ETB receptor antagonist), YM-254890 (a selective Gq protein inhibitor), PTX (a selective Gi protein inhibitor) and NF449 (a Gs protein inhibitor) on the ET-1-induced inhibition of insulinstimulated Akt phosphorylation in L6 myotubes. The cells were treated with 30 nM ET-1 for indicated times during treatment with 100 nM insulin for 60 min. The cells were treated with one of the drugs for 30 min (except PTX for 18 h) before treatment with 100 nM insulin for 60 min. (A) Representative immunoblots obtained using antibodies to phospho-Akt at Thr308 [p-Akt (T308)], phospho-Akt at Ser473 [p-Akt (S473)] and total Akt (t-Akt). (B) ET-1-induced changes in the ratio of phosphorylated Akt to t-Akt. Ordinate represents Akt phosphorylation responses, which are normalized to the level of insulin-stimulated Akt phosphorylation in L6 myotubes without treatment with ET-1, vehicle, antagonists or inhibitors. Data are presented as means ± SEM of the results obtained from five to six experiments. *P < 0.05 versus its control (100 nM insulin alone).
|
